Pfizer should partner with Sanofi

PfizerViagraTablet

It's day three of the Pfizer-Sanofi merger watch. Sanofi-Aventis shares are up 5.5 percent on continued rumors of a Pfizer investment in its business. Now, experts are saying that a Sanofi acquisition wouldn't be prudent for Pfizer--but a partnership would.

If Pfizer just bought a stake in Sanofi, it could share in the French company's revenues. Sanofi would get access to Pfizer's U.S. sales force. And the companies wouldn't have to get the French government's blessing on this sort of deal--a blessing that might be hard to come by.

- read the report from Fortune

Related Articles:
Pfizer-Sanofi match not made in heaven? Report
Pfizer, Wyeth merger bad idea? Report

Read more on: Pfizer | Sanofi-Aventis

Read more on

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.